Heparin Articles
1st Approval For Novartis' Exelon; 2nd For Revasc
7 August 1997
Emisphere Completes Phase I Heparin Trial
16 July 1997
Texas Files NDA For Novastan
9 July 1997
First Approval Of Wyeth's LMWH Normiflo
9 June 1997
Rhone-Poulenc Rorer Expands In Singapore
19 May 1997
Texas Reveals Positive Ph III Novastan Data
23 April 1997
Synthelabo Presents 1996 Highlights, New Research
21 April 1997
First Launch Of HMR's Lepirudin Set For May
21 April 1997
Ph II Data With Texas' Novastan In Acute MI
7 April 1997
Tirofiban Cuts Mortality In Unstable Angina Patients
26 March 1997
UK Industry Code Of Practice In 1996
24 March 1997
GUSTO III: Activase Fends Off Retevase Challenge
20 March 1997
R-PR Files To Market Lovenox For Angina
20 March 1997
Fragmin Licensed For Unstable CAD
10 March 1997
Integrilin Fails To Get US Approval Recommendation
10 March 1997
Strong Sales At Sanofi In 4th Qtr
17 February 1997
ESSENCE Study Finds Lovenox Beats Heparin
25 November 1996
Six-Month EPILOG Data Reveal Sustained Benefits
18 November 1996
Costs Of Deep Vein Thrombosis And Pulmonary Embolism Assessed
4 November 1996
Atlantic Reports CT-1/CT-2 Data
4 November 1996
R-PR's 18% EPS Rise Drives Parent Co In 3rd Qtr
4 November 1996
First Phase II Data With Argatroban In AMI
28 October 1996
Synthelabo Pipeline Supports "Seven Key Product" Strategy
21 October 1996
R-PR Divulges R&D Pipeline Developments
23 September 1996
AHA Issues Guidelines On tPA Use In Strokes
16 September 1996
Studies Show The Effectiveness Of R-PR's Lovenox
9 September 1996
Argatroban Gets Stroke Indication In Japan
24 June 1996
Pharmacia And Kissei To Copromote Fragmin
29 April 1996
IBEX' Neutralase Enters Phase II
15 April 1996
ReoPro Reduces Mortality In CAPTURE Study
15 April 1996
GUSTO II Casts Doubt On Revasc Future
1 April 1996
Oral Heparin In Trials Soon?
1 April 1996
Merck's Aggrastat Disappoints
1 April 1996
HERO Study Finds Hirulog Benefit In Heart Attack
1 April 1996
LMWH For Home Treatment Of DVT
25 March 1996
LMWH For Home Treatment Of DVT
25 March 1996
"Favorable Growth " At Sanofi In 1995
25 March 1996
Corvas Selects Lead Antithrombotic
11 March 1996
Atlantic: Epitomizing The "Virtual" Firm Concept
11 March 1996
NCEs In 1995: A Good Range Of Novel Drugs
29 January 1996
Positive Results For ReoPro In CAPTURE Trial
8 January 1996
Activase Shows Promise In Stroke; Filing Set For 1996?
8 January 1996
TIMI 9b; Hirudin Shows No Advantage Over Heparin
4 December 1995
New Trials For R-PR's LMWH In Unstable Angina
4 December 1995
Corvas Antithombotic Better Than LMWH
27 November 1995
IBEX' Neutralase For Heparin Neutralization
13 November 1995
Elan And Emisphere Tech Plan JV And Drug Delivery Deal
30 October 1995
Planning For Success In An Uncertain Japan
2 October 1995
OASIS Pilot Results Suggest Hirudin Benefit
11 September 1995
Early FRIC Data Back Fragmin Use In UA
4 September 1995
FRISC Trial Casts Light On Antithrombotic Use
4 September 1995
Marriage Of Pharmacia And Upjohn Will Create New $13 Bill Drug Group
4 September 1995
Ibex Completes Phase Ia Neutralase Trials
21 August 1995
Reteplase Holds Promise For Acute MI Patients
14 August 1995
Merck pipline report
3 July 1995
IBEX' Neutralase In Phase I Testing
5 June 1995
Pharmacia Results Down But Ahead Of Expectations
22 May 1995
First EU Launch For ReoPro, In UK
15 May 1995
Repligen's recombinant rPF4
8 May 1995
S-P Collaboration On Cor's Integrelin
24 April 1995
US Neurotherapeutics And GI Market Forecasts
24 April 1995
Ciba Reveals Pipeline With Broad Reach
17 April 1995
BASF Optimistic On Future With Good 1995 Start
3 April 1995
Productivity Improvements Boost Pharmacia Earnings
20 March 1995
US Panel Backs Flolan Approval For PPH
6 March 1995
Repligen Reins Back On Drug Programs
27 February 1995
Novo Nordisk Divests Anticoagulants
23 January 1995
US Approval For Centocor's ReoPro
9 January 1995
Fragmin Approved In USA
9 January 1995
Xoma Drops CD5 Plus For Graft-Versus-Host Disease
9 January 1995
TLC's Liposomal Prostaglandin
19 December 1994
UK MCA Fee Proposals for Drug-Device Combinations
19 December 1994
Biotech Woes Continue As More Drugs Meet Trouble
7 November 1994
GUSTO IIa Halted Amid Safety Concerns
7 November 1994
Fragmin Sales
7 November 1994
Pharmacia's Fragmin After Bypass Grafting
10 October 1994
Xoma Receives US Patent
26 September 1994
Centocor R&D To Support Profitability in 1995?
22 August 1994
Repligen Halts AIDS Vaccine Program
1 August 1994
Genzyme Forms Wound Healing Specialist Arm
1 August 1994
KNOLL/MITSUI IN MDR LINK-UP
11 July 1994
US ANTITHROMBOSIS MARKET FORECASTS
27 June 1994
CENTOCOR'S REOPRO NEARS APPROVAL
20 June 1994
UNCLOGGING THE ISSUES IN THROMBOLYSIS
13 June 1994
KNOLL'S ANCROD STARTS PH III IN USA
30 May 1994
NEW HORIZONS FOR THE USE OF LMW HEPARIN
30 May 1994
PHARMACIA OPERATING INCOME ROCKETS
23 May 1994
1994: AN IMPORTANT YEAR FOR XOMA?
2 May 1994
PH II RESULTS OF PROSCAR BALDNESS TRIALS
25 April 1994
FDA REQUESTS MORE INFO ON ASTENOSE
4 April 1994
ISSUES RAISED AND TRIALS PRESENTED AT ACC
28 March 1994
J&J DRUG-COATED STENT IMPLANTED INTO PATIENTS
14 March 1994
MERCK FILES NDAs FOR COZAAR WORLDWIDE
21 February 1994
XOMA SEEKS OTHER USES FOR NEUPREX
7 February 1994
ROUND-UP OF 1993'S NEW CHEMICAL ENTITIES
31 January 1994
FRAGMIN APPROVABLE, SAYS FDA
24 January 1994
FOURNIER TALKS WITH PHARMACIA ON PIERREL
17 January 1994
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
